查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2012370

基因组编辑市场：按技术、治疗领域、递送方式、应用和最终用户划分－2026-2032年全球市场预测

Genome Editing Market by Technology, Therapeutic Area, Delivery Method, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，基因组编辑市值将达到 50.1 亿美元，到 2026 年将成长到 54.9 亿美元，到 2032 年将达到 103.8 亿美元，复合年增长率为 10.96%。

主要市场统计数据
基准年 2025 50.1亿美元
预计年份：2026年 54.9亿美元
预测年份 2032 103.8亿美元
复合年增长率 (%) 10.96%

对不断发展的基因组编辑生态系统进行了简洁且权威的概述，将科学进步与实践和政策现实相结合。

基因组编辑已从一项小众的实验室技术发展成为现代生命科学的核心支柱，彻底改变了研究范式、治疗方法开发和农业创新。过去十年，精准编辑化学和递送系统的进步使得人们能够触及以前难以企及的基因标靶。因此，转化应用范围已扩展至基因校正、细胞工程以及作物和牲畜性状改良，而利用编辑后的生物体进行高价值生物製造也已开始在工业生产中应用。

详细概述了正在重新定义基因组编辑整个领域的优先事项和价值创造的科学、监管和营运变化。

在基因组编辑领域，正在发生多项变革性变化，重塑研究重点和商业策略。首先，编辑平台的准确性和安全性不断提高，正在改变治疗和农业领域风险效益评估的方式，推动研究从探索性研究转向转化和临床计画。这种转变凸显了递送技术和有效载荷优化作为实现临床可行性的关键要素的重要性。

对 2025 年关税措施如何重塑整个基因组编辑价值链的供应链、筹资策略和营运决策进行严格分析。

关税体系和跨境贸易政策的变化正对基因组编辑生态系统产生重大影响，波及试剂分销、设备进口以及下游生产的成本基础。 2025年累积的关税进一步凸显了供应链韧性和供应商多元化的重要性，因为企业面临着酵素、核酸合成服务和专用实验室设备等关键投入品前置作业时间週期延长和接收成本增加的问题。

策略性细分框架，分析技术、应用、最终使用者、治疗领域和管理方法，以揭示可行的方案和投资的见解。

细分市场提供了必要的分析框架，将科学上的细微差别转化为商业性洞察。依技术分析，该市场包括碱基编辑（包括腺嘌呤和胞嘧啶碱基编辑器）、CRISPR系统（进一步细分为Cas12、Cas13和Cas9变体）、先导编辑、Megatal、TALEN和ZFN。每种技术在准确性、有效载荷限制和脱靶效应方面都存在独特的权衡取舍。这种详细的分类至关重要，因为平台特性决定了下游流程的选择，例如递送方法、标靶选择和安全性测试，从而影响可实施的适应症类型和方案设计。

区域比较分析重点阐述了不同的法规环境、製造能力和研究生态系统如何塑造世界各地市场的基因组编辑策略。

区域趋势对技术采纳、监管策略和伙伴关係模式有决定性影响。在美洲，活跃的创业投资活动、集中的临床试验基础设施以及紧密的转化研究中心网络，推动了新型基因编辑疗法从发现到早期临床开发的快速进展。这些区域优势使美洲成为合作科学网路和大规模生物技术丛集的中心，加速了转化研究的发展势头。

对平台创新公司、药物研发公司、服务供应商和製造专家的企业策略进行清晰分析，这些策略能够带来竞争优势。

基因组编辑领域的企业级发展趋势呈现出多元化的模式，涵盖了平台技术先驱、垂直整合的研发公司以及专业服务供应商。专注于平台的公司致力于提高编辑特异性、拓展标靶范围，并建立模组化系统，从而实现跨多个应用领域的授权和合作。这些机构通常会在研发方面投入巨资，以保持其在碱基编辑、先导编辑和核酸酶优化等核心技术领域的主导地位。

为高阶主管提供如何协调技术开发、伙伴关係、监管参与和业务永续营运连续性以实现可持续成长的实用策略指导。

产业领导者必须采取多方面且切实可行的策略，将技术潜力转化为商业性成功。首先，递送技术的创新和有效载荷工程的投入至关重要，因为改进基因编辑系统到达目标细胞和组织的方式，对临床可行性和农业应用有显着影响。企业应在专案设计的早期阶段优先考虑基因编辑化学和递送方法的整合，以降低后续开发风险。

检验透过高度透明和严谨的混合方法研究途径来验证我们的发现，该方法整合了专家访谈、技术文献整合和基于情境的分析。

本调查方法结合了来自一手和二手调查的定性调查方法，并运用严谨的证据整合方法，旨在深入了解基因组编辑生态系统。一手调查包括对来自学术机构、受託研究机构（CRO）、生物技术开发公司和药物开发公司等各领域专家的结构化访谈。这些访谈提供了有关实际限制、开发进度和战略重点的背景信息，而这些信息未必会在已发表的文献中披露。

我们透过简洁、综合的分析，将技术创新与监管、道德和营运要求连结起来，从而引导决策者制定有影响力的方案。

基因组编辑技术的进步体现了多种因素的汇聚：编辑化学技术的日趋成熟、递送方法日臻完善、监管预期不断变化以及经济压力持续演进。这些因素共同构成了一个动态环境，在这个环境中，策略灵活性、技术卓越性和营运稳健性决定了哪些专案能够成功地从概念转化为成果。相关人员在应对这一环境时，必须在平台重点、伙伴关係结构和地域部署方面做出审慎的选择。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 基因组编辑市场：依技术划分

  • 基础编辑
    • 腺嘌呤碱基编辑器
    • 胞嘧啶碱基编辑器
  • CRISPR
    • Cas12
    • Cas13
    • Cas9
  • 大麦克
  • 主编
  • 天赋
  • ZFN

第九章：基因组编辑市场：依治疗领域划分

  • 循环系统
  • 遗传性疾病
  • 感染疾病
  • 神经病学
  • 肿瘤学

第十章：基因组编辑市场：以交付方式划分

  • 非病毒
    • 电穿孔
    • 脂质奈米颗粒
  • 物理方法
    • 遗传性癌症
    • 显微注射
  • 病毒载体

第十一章 基因组编辑市场：依应用领域划分

  • 农业
    • 作物改良
    • 畜牧改良
  • 工业生物技术
    • 生质燃料
    • 生物製造
  • 调查
    • 基础研究
    • 药物发现
  • 治疗药物
    • 细胞疗法
    • 基因治疗

第十二章 基因组编辑市场：依最终使用者划分

  • 学术机构
  • 合约研究机构
  • 製药和生物技术公司

第十三章 基因组编辑市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 基因组编辑市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 基因组编辑市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国基因组编辑市场

第十七章：中国基因组编辑市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Arbor Biotechnologies Inc
  • Beam Therapeutics Inc
  • Caribou Biosciences Inc
  • Century Therapeutics Inc
  • CRISPR Therapeutics AG
  • Editas Medicine Inc
  • GenScript
  • Gilead Sciences Inc
  • Horizon Discovery Group PLC
  • Intellia Therapeutics Inc
  • Mammoth Biosciences
  • Merck KGaA
  • Metagenomi
  • Pairwise Plants
  • Poseida Therapeutics Inc
  • Precision BioSciences Inc
  • Prime Medicine Inc
  • Regeneron Pharmaceuticals Inc
  • Sangamo Therapeutics Inc
  • Scribe Therapeutics
  • Tessera Therapeutics Inc
  • Thermo Fisher Scientific Inc
  • Vertex Pharmaceuticals Incorporated
  • Verve Therapeutics Inc
Product Code: MRR-431C35F6C15D

The Genome Editing Market was valued at USD 5.01 billion in 2025 and is projected to grow to USD 5.49 billion in 2026, with a CAGR of 10.96%, reaching USD 10.38 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.01 billion
Estimated Year [2026] USD 5.49 billion
Forecast Year [2032] USD 10.38 billion
CAGR (%) 10.96%

A concise and authoritative orientation to the transforming genome editing ecosystem that integrates scientific advances with operational and policy realities

Genome editing has evolved from a niche laboratory capability into a central pillar of modern life sciences, transforming research paradigms, therapeutic development, and agricultural innovation. Over the past decade, advances in precision editing chemistries and delivery systems have increased the feasibility of addressing previously intractable genetic targets. As a result, translational pipelines have broadened to include gene correction, cell engineering, and trait improvement in crops and livestock, while industrial processes have begun to leverage edited organisms for higher-value biomanufacturing.

Consequently, the ecosystem now spans academic laboratories, contract research organizations, biotechnology firms, and large pharmaceutical companies. Each stakeholder group demands differentiated evidence: bench-level validation for researchers, scalable manufacturing approaches for industry, and regulatory and reimbursement intelligence for commercial development. Thus, an integrated synthesis of technological capabilities, application-specific constraints, and regulatory context is essential for informed decision-making.

Moreover, geopolitical and trade dynamics have introduced new variables into supply chains and capital allocation. These external pressures interact with technical progress to influence where and how genome editing innovations are developed, tested, and commercialized. Therefore, readers should expect a holistic assessment that connects scientific trajectories with policy shifts and market-relevant operational considerations.

An in-depth synthesis of scientific, regulatory, and operational shifts that are redefining priorities and value creation across the genome editing landscape

The landscape of genome editing is undergoing multiple transformative shifts that are reshaping research priorities and commercial strategies. First, precision and safety improvements in editing platforms have altered risk-benefit calculations across therapeutic and agricultural applications, prompting a move from exploratory research toward translational and clinical programs. This transition has elevated the importance of delivery technologies and payload optimization as critical enablers of clinical viability.

Second, modularity and interoperability of editing systems are accelerating innovation cycles. Platforms such as base editors, prime editors, and CRISPR-focused nucleases can be combined with evolving delivery vehicles to create tailored solutions for diverse targets, thereby enabling a wider set of stakeholders to pursue differentiated value propositions. Consequently, cross-disciplinary collaboration between molecular biologists, delivery specialists, and process engineers is increasing.

Third, regulatory frameworks are adapting, with agencies worldwide refining guidance on safety assessments, off-target evaluation, and long-term follow-up requirements. These regulatory refinements are influencing development timelines and evidentiary needs, while also opening pathways for earlier dialog between developers and regulators. Simultaneously, heightened public and investor scrutiny places a premium on transparent safety data and robust patient engagement strategies.

Finally, macroeconomic and trade factors are prompting organizations to reassess supply chains, reagent sourcing, and manufacturing footprints. In response, firms are diversifying vendor relationships and investing in regional capabilities to mitigate exposure to external shocks. Taken together, these shifts demand agile strategies that integrate scientific foresight with pragmatic operational planning.

A rigorous analysis of how 2025 tariff measures have reshaped supply chains, procurement strategies, and operational decision-making across the genome editing value chain

Policy shifts in tariff regimes and cross-border trade have material implications for the genome editing ecosystem, affecting reagent flows, instrument imports, and the cost base of downstream manufacturing. Cumulative tariffs imposed in 2025 have amplified the importance of supply chain resilience and vendor diversification, as companies experienced increased lead times and higher landed costs for critical inputs such as enzymes, nucleic acid synthesis services, and specialized laboratory equipment.

As a result, organizations have accelerated localization efforts and sought alternative suppliers with regional capacity. In parallel, procurement teams have adopted multi-sourcing strategies and longer-term contracting to stabilize supply and price exposure. These adjustments have influenced project sequencing and capital allocation decisions, particularly for firms managing clinical pipelines with tight timelines.

Moreover, tariff-driven cost pressures have shifted negotiation dynamics between manufacturers of instruments and reagents and their downstream customers. Some suppliers responded by offering bundled services, flexible financing, or on-shore assembly options to maintain competitiveness. From a strategic perspective, these developments have increased the appeal of vertically integrated models and in-house manufacturing capabilities for larger institutions seeking to control critical production steps.

In addition, tariff impacts have varied across applications and end users, with academic institutes and smaller developers often more exposed to immediate cost increases than well-capitalized pharmaceutical partners. Consequently, collaborative procurement consortia and shared core facilities have emerged as pragmatic responses, allowing multiple organizations to spread fixed costs and maintain access to key technologies despite tariff-related disruptions.

A strategic segmentation framework that dissects technology, application, end-user, therapeutic area, and delivery method to reveal actionable program and investment implications

Segmentation provides the analytical scaffolding needed to translate scientific nuance into commercial insight. When analyzed by technology, the market includes Base Editing with its Adenine Base Editor and Cytosine Base Editor subtypes, CRISPR systems further differentiated into Cas12, Cas13, and Cas9 variants, Prime Editing, Megatal, TALEN, and ZFN, each presenting distinct technical trade-offs in precision, payload constraints, and off-target profiles. This granularity is critical because platform attributes determine downstream choices in delivery, target selection, and safety testing, thereby influencing the types of indications and program designs that are feasible.

When framed by application, key trajectories emerge across Agricultural applications focused on Crop Improvement and Livestock Improvement, Industrial Biotechnology use cases such as Biofuels and Biomanufacturing, Research applications that span Basic Research and Drug Discovery, and Therapeutics encompassing Cell Therapy and Gene Therapy. These application segments require different evidence bases, with agricultural and industrial players prioritizing trait stability and scale, while therapeutic developers emphasize clinical safety, efficacy, and regulatory alignment.

In terms of end users, the ecosystem spans Academic Institutes, Contract Research Organizations, and Pharmaceutical and Biotechnology companies, each with distinct operational models, funding cycles, and access to scale-up capabilities. Academic centers often act as innovation hubs and early proof-of-concept generators, CROs provide specialized expertise and scalable execution, and pharmaceutical and biotech firms focus on commercial development and regulatory pathways.

Therapeutic area segmentation identifies priority domains including Cardiology, Genetic Disorders, Infectious Diseases, Neurology, and Oncology, which differ markedly in biological complexity, patient populations, and clinical trial design considerations. Delivery method segmentation further clarifies feasibility: Nonviral approaches such as Electroporation and Lipid Nanoparticles offer transient expression profiles and reduced immunogenicity risks, Physical Methods like Gene Gun and Microinjection enable ex vivo manipulation or localized delivery, and Viral Vector strategies remain essential for durable in vivo expression. Understanding how these segmentation lenses intersect enables stakeholders to align platform selection with target indications and development strategies.

A comparative regional analysis highlighting how distinct regulatory environments, manufacturing capabilities, and research ecosystems shape genome editing strategies across global markets

Regional dynamics exert a decisive influence on technology adoption, regulatory strategy, and partnership models. In the Americas, strong venture capital activity, a concentration of clinical trial infrastructure, and a dense network of translational research centers have supported rapid progression of novel editing therapies from discovery into early clinical development. These regional strengths make the Americas a focal point for collaborative scientific networks and sizable biotech clusters that accelerate translational momentum.

In Europe, the Middle East & Africa region, regulatory harmonization across multiple jurisdictions and a diverse payer landscape shape development tactics. European research institutions continue to contribute foundational scientific advances while startups and larger pharmaceutical firms navigate complex reimbursement and ethical frameworks. Meanwhile, investments in manufacturing capacity and strategic public-private partnerships are emerging as levers to maintain competitiveness in advanced therapies.

In the Asia-Pacific, rapid scaling of manufacturing capability, a growing base of skilled scientists, and proactive government initiatives to support biotechnology innovation have led to expanding research and commercialization pathways. Additionally, regional differences in regulatory timelines and clinical trial enrollment dynamics have encouraged multinational developers to adopt flexible clinical strategies that leverage Asia-Pacific strengths for expedited patient recruitment and cost-efficient development.

Across these regions, stakeholders increasingly adopt hybrid strategies that combine local capabilities with cross-border partnerships, thereby optimizing access to talent, capital, and patient populations while managing regional regulatory and supply chain variability.

A clear-eyed examination of company strategies across platform innovators, therapeutic developers, service providers, and manufacturing specialists that drive competitive positioning

Company-level dynamics in genome editing reflect a spectrum of archetypes ranging from platform technology pioneers to vertically integrated developers and specialized service providers. Platform-focused firms concentrate on improving editing specificity, expanding target scope, and creating modular systems that can be licensed or partnered into diverse application areas. These organizations typically invest heavily in R&D to maintain lead positions in core technologies such as base editing, prime editing, and nuclease optimization.

Therapeutic developers often follow licensing and collaboration pathways to combine platform strengths with clinical and regulatory expertise, thereby accelerating the translation of early-stage discoveries into clinical candidates. Service providers and contract research organizations have adapted by bundling end-to-end capabilities that include target validation, delivery optimization, and GLP-compliant safety testing, creating turnkey solutions for sponsors seeking to outsource technical complexity.

Manufacturing and supply chain specialists are also evolving to support advanced therapy production, with investments in scalable fill-finish, vector production, and quality systems. In addition, there is a growing emphasis on strategic partnerships that align platform owners with manufacturing specialists and commercial partners to de-risk late-stage development and enable broader market access. Collectively, these company-level strategies illustrate how ecosystem participants position themselves to capture value at different points in the innovation-to-commercialization continuum.

Action-oriented strategic guidance for executives to align technology development, partnerships, regulatory engagement, and operational resilience for sustainable growth

Industry leaders must adopt multifaceted, pragmatic strategies to convert technological promise into commercial success. First, investing in delivery innovation and payload engineering is essential, because improvements in how editing systems reach target cells and tissues materially affect clinical feasibility and agricultural application outcomes. Companies should prioritize integration between editing chemistry and delivery modality early in program design to reduce downstream development risk.

Second, leaders should pursue flexible partnership models that balance proprietary control with the practical benefits of collaboration. Strategic alliances with specialized contract research organizations, manufacturing partners, and regional development hubs can accelerate time to clinic while preserving optionality for commercialization. In parallel, developing a robust regulatory affairs capability and engaging regulators early in development can smooth approval pathways and define acceptable safety endpoints.

Third, operational resilience must be elevated through supply chain diversification, regional manufacturing planning, and long-term supplier agreements. These measures mitigate exposure to trade disruptions and ensure continuity of clinical and commercial programs. Moreover, companies should strengthen data governance and ethical oversight frameworks to sustain public trust and meet evolving societal expectations.

Finally, firms should align investment decisions with clear go-to-market strategies that consider therapeutic area complexity, patient recruitment dynamics, and reimbursement scenarios. By matching platform strengths to indications where scientific rationale, regulatory feasibility, and commercial upside converge, leaders can prioritize programs with the highest prospective impact and resource efficiency.

A transparent and rigorous mixed-methods research approach that integrates expert interviews, technical literature synthesis, and scenario-based analysis to validate findings

The research methodology combines primary and secondary qualitative techniques with rigorous evidence synthesis to deliver robust insights into the genome editing ecosystem. Primary research includes structured interviews with domain experts across academic institutions, contract research organizations, biotechnology developers, and therapeutic sponsors. These dialogues provide context on practical constraints, development timelines, and strategic priorities that are not always evident in public literature.

Secondary research synthesizes peer-reviewed publications, regulatory guidance documents, patent filings, and corporate disclosures to construct a comprehensive technical and policy narrative. Where appropriate, technical white papers, conference proceedings, and preprint literature were reviewed to capture the most recent advances in editing platforms and delivery systems. Triangulation across these sources ensures that conclusions are grounded in reproducible evidence and expert validation.

Analytical frameworks employed in the study include technology readiness assessments, value-chain mapping, and scenario-based risk analysis. Sensitivity checks were performed through iterative expert review, and findings were validated through cross-sector workshops to ensure relevance to both R&D and commercial stakeholders. Confidentiality protocols were applied to primary interviews to protect proprietary inputs and encourage candid commentary.

A concise synthesis that connects technical innovation with regulatory, ethical, and operational imperatives to guide decision-makers toward impactful programs

The trajectory of genome editing is characterized by converging forces: technical refinement of editing chemistries, maturation of delivery approaches, evolving regulatory expectations, and shifting economic pressures. Together, these forces create a dynamic environment in which strategic agility, technical excellence, and operational robustness determine which programs progress successfully from concept to impact. As stakeholders navigate this environment, they will need to make disciplined choices about platform focus, partnership structures, and geographic deployment.

Importantly, the most promising near-term opportunities are those that effectively pair technical feasibility with clear translational pathways, whether in therapeutics, agriculture, or industrial biotechnology. Concurrently, managing supply chain exposure and investing in compliance and ethical governance will be critical to sustaining long-term momentum. By synthesizing technological, regulatory, and commercial considerations, organizations can prioritize initiatives with the highest potential to deliver meaningful scientific and societal benefits.

Ultimately, success in genome editing will be defined not only by scientific breakthroughs but by the capacity of organizations to operationalize those breakthroughs at scale, responsibly and resiliently.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Genome Editing Market, by Technology

  • 8.1. Base Editing
    • 8.1.1. Adenine Base Editor
    • 8.1.2. Cytosine Base Editor
  • 8.2. Crispr
    • 8.2.1. Cas12
    • 8.2.2. Cas13
    • 8.2.3. Cas9
  • 8.3. Megatal
  • 8.4. Prime Editing
  • 8.5. Talen
  • 8.6. Zfn

9. Genome Editing Market, by Therapeutic Area

  • 9.1. Cardiology
  • 9.2. Genetic Disorders
  • 9.3. Infectious Diseases
  • 9.4. Neurology
  • 9.5. Oncology

10. Genome Editing Market, by Delivery Method

  • 10.1. Nonviral
    • 10.1.1. Electroporation
    • 10.1.2. Lipid Nanoparticles
  • 10.2. Physical Methods
    • 10.2.1. Gene Gun
    • 10.2.2. Microinjection
  • 10.3. Viral Vector

11. Genome Editing Market, by Application

  • 11.1. Agricultural
    • 11.1.1. Crop Improvement
    • 11.1.2. Livestock Improvement
  • 11.2. Industrial Biotechnology
    • 11.2.1. Biofuels
    • 11.2.2. Biomanufacturing
  • 11.3. Research
    • 11.3.1. Basic Research
    • 11.3.2. Drug Discovery
  • 11.4. Therapeutics
    • 11.4.1. Cell Therapy
    • 11.4.2. Gene Therapy

12. Genome Editing Market, by End User

  • 12.1. Academic Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical Biotech

13. Genome Editing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Genome Editing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Genome Editing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Genome Editing Market

17. China Genome Editing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Arbor Biotechnologies Inc
  • 18.6. Beam Therapeutics Inc
  • 18.7. Caribou Biosciences Inc
  • 18.8. Century Therapeutics Inc
  • 18.9. CRISPR Therapeutics AG
  • 18.10. Editas Medicine Inc
  • 18.11. GenScript
  • 18.12. Gilead Sciences Inc
  • 18.13. Horizon Discovery Group PLC
  • 18.14. Intellia Therapeutics Inc
  • 18.15. Mammoth Biosciences
  • 18.16. Merck KGaA
  • 18.17. Metagenomi
  • 18.18. Pairwise Plants
  • 18.19. Poseida Therapeutics Inc
  • 18.20. Precision BioSciences Inc
  • 18.21. Prime Medicine Inc
  • 18.22. Regeneron Pharmaceuticals Inc
  • 18.23. Sangamo Therapeutics Inc
  • 18.24. Scribe Therapeutics
  • 18.25. Tessera Therapeutics Inc
  • 18.26. Thermo Fisher Scientific Inc
  • 18.27. Vertex Pharmaceuticals Incorporated
  • 18.28. Verve Therapeutics Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GENOME EDITING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL GENOME EDITING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL GENOME EDITING MARKET SIZE, BY ADENINE BASE EDITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL GENOME EDITING MARKET SIZE, BY CYTOSINE BASE EDITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENOME EDITING MARKET SIZE, BY CAS12, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL GENOME EDITING MARKET SIZE, BY CAS13, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GENOME EDITING MARKET SIZE, BY CAS9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENOME EDITING MARKET SIZE, BY MEGATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL GENOME EDITING MARKET SIZE, BY PRIME EDITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL GENOME EDITING MARKET SIZE, BY TALEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL GENOME EDITING MARKET SIZE, BY ZFN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GENOME EDITING MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL GENOME EDITING MARKET SIZE, BY GENETIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL GENOME EDITING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL GENOME EDITING MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GENOME EDITING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GENOME EDITING MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL GENOME EDITING MARKET SIZE, BY LIPID NANOPARTICLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL GENOME EDITING MARKET SIZE, BY GENE GUN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL GENOME EDITING MARKET SIZE, BY MICROINJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL GENOME EDITING MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL GENOME EDITING MARKET SIZE, BY CROP IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL GENOME EDITING MARKET SIZE, BY LIVESTOCK IMPROVEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL GENOME EDITING MARKET SIZE, BY BIOFUELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL GENOME EDITING MARKET SIZE, BY BIOMANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL GENOME EDITING MARKET SIZE, BY BASIC RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL GENOME EDITING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL GENOME EDITING MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENOME EDITING MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL GENOME EDITING MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL GENOME EDITING MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL GENOME EDITING MARKET SIZE, BY PHARMACEUTICAL BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL GENOME EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS GENOME EDITING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 202. MIDDLE EAST GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 204. MIDDLE EAST GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 205. MIDDLE EAST GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 206. MIDDLE EAST GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 207. MIDDLE EAST GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 208. MIDDLE EAST GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 210. MIDDLE EAST GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 212. MIDDLE EAST GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. AFRICA GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. AFRICA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. AFRICA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 217. AFRICA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 218. AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 219. AFRICA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 220. AFRICA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 221. AFRICA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 222. AFRICA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. AFRICA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 224. AFRICA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 225. AFRICA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 226. AFRICA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 227. AFRICA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 233. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 234. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 235. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 236. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL GENOME EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 243. ASEAN GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 244. ASEAN GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. ASEAN GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 246. ASEAN GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 247. ASEAN GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 248. ASEAN GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 249. ASEAN GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 250. ASEAN GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 251. ASEAN GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. ASEAN GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 253. ASEAN GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 254. ASEAN GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 255. ASEAN GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 256. ASEAN GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 257. GCC GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. GCC GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. GCC GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 260. GCC GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 261. GCC GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 262. GCC GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 263. GCC GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 264. GCC GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 265. GCC GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 266. GCC GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 267. GCC GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. GCC GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 269. GCC GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 270. GCC GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 272. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 274. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 276. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 277. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 278. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 279. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 280. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 282. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 284. EUROPEAN UNION GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. BRICS GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. BRICS GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. BRICS GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 288. BRICS GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 289. BRICS GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 290. BRICS GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 291. BRICS GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 292. BRICS GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 293. BRICS GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. BRICS GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 295. BRICS GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. BRICS GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 297. BRICS GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 298. BRICS GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 299. G7 GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 300. G7 GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. G7 GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 302. G7 GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 303. G7 GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 304. G7 GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 305. G7 GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 306. G7 GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 307. G7 GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 308. G7 GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 309. G7 GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. G7 GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 311. G7 GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 312. G7 GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. NATO GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 314. NATO GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 315. NATO GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 316. NATO GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 317. NATO GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 318. NATO GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 319. NATO GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 320. NATO GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 321. NATO GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. NATO GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 323. NATO GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 324. NATO GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 325. NATO GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 326. NATO GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. GLOBAL GENOME EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 328. UNITED STATES GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 329. UNITED STATES GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 330. UNITED STATES GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 331. UNITED STATES GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 332. UNITED STATES GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 333. UNITED STATES GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 334. UNITED STATES GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 335. UNITED STATES GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 336. UNITED STATES GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 337. UNITED STATES GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 338. UNITED STATES GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 339. UNITED STATES GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 340. UNITED STATES GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 341. UNITED STATES GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 342. CHINA GENOME EDITING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 343. CHINA GENOME EDITING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 344. CHINA GENOME EDITING MARKET SIZE, BY BASE EDITING, 2018-2032 (USD MILLION)
  • TABLE 345. CHINA GENOME EDITING MARKET SIZE, BY CRISPR, 2018-2032 (USD MILLION)
  • TABLE 346. CHINA GENOME EDITING MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 347. CHINA GENOME EDITING MARKET SIZE, BY DELIVERY METHOD, 2018-2032 (USD MILLION)
  • TABLE 348. CHINA GENOME EDITING MARKET SIZE, BY NONVIRAL, 2018-2032 (USD MILLION)
  • TABLE 349. CHINA GENOME EDITING MARKET SIZE, BY PHYSICAL METHODS, 2018-2032 (USD MILLION)
  • TABLE 350. CHINA GENOME EDITING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. CHINA GENOME EDITING MARKET SIZE, BY AGRICULTURAL, 2018-2032 (USD MILLION)
  • TABLE 352. CHINA GENOME EDITING MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. CHINA GENOME EDITING MARKET SIZE, BY RESEARCH, 2018-2032 (USD MILLION)
  • TABLE 354. CHINA GENOME EDITING MARKET SIZE, BY THERAPEUTICS, 2018-2032 (USD MILLION)
  • TABLE 355. CHINA GENOME EDITING MARKET SIZE, BY END USER, 2018-2032 (USD